Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27409381 | 0.88 | SMPD3 (0.56) | SMPD3ALDH1A1CYP3A4LOXL2HDAC2 | |
| SCHEMBL15010747 | 0.81 | SMPD3 (0.60) | SMPD3TSHRLOXL2PDPK1ADRB2 | |
| SCHEMBL1068648 | 0.80 | LOXL2 (0.55) | SMPD3ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL8234511 | 0.80 | PTGDR2 (0.52) | SMPD3LOXL2PDPK1ADRB2ECE1 | |
| SCHEMBL26832841 | 0.79 | SMPD3 (0.57) | SMPD3LOXL2PDPK1ADRB2ECE1 | |
| SCHEMBL1830952 | 0.79 | ALDH1A1 (0.53) | SMPD3ALDH1A1CYP3A4HSD17B10TSHR | |
| SCHEMBL22000048 | 0.78 | SMPD3 (0.56) | SMPD3LOXL2PDPK1ADRB2ECE1 | |
| SCHEMBL8078437 | 0.78 | SMPD3 (0.52) | SMPD3ALDH1A1LOXL2HDAC2PDPK1 | |
| SCHEMBL11309299 | 0.77 | SMPD3 (0.73) | SMPD3ALDH1A1HSD17B10TSHRPDPK1 | |
| SCHEMBL1307678 | 0.76 | TUBB4A (0.56) | HDAC2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11053241-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| WO-2020112937-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20200172540-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | SMPD3 3923/4885ALDH1A1 4827/4885CYP3A4 4404/4885 |
| US-11053241-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | SMPD3 3923/4885ALDH1A1 4827/4885CYP3A4 4404/4885 |
| US-20200172540-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SMPD3 3923/4885ALDH1A1 4827/4885CYP3A4 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.